Patients who are receiving any other investigational agent(s) Patients who are currently receiving any other investigational agent Patient is currently receiving or has received another investigational agent within weeks prior to day of study Patients who are currently receiving another investigational agent are excluded Patients may not be receiving any other investigational agent Receiving any other agent which would be considered as a treatment for the lymphoma Currently receiving any other investigational agent or received an investigational agent within last days of study entry. Patient is currently receiving or has received another investigational agent within weeks prior to study day Receiving other investigational agent concomitantly Receiving any other investigational agent that would be considered as a treatment for the lymphoma Patients who are currently receiving another investigational agent are excluded Receiving any approved or investigational anti-cancer agent other than those provided for in this study Participants who are receiving an investigational agent(s) Patients receiving another investigational agent Receiving any other investigational agent(s) or has received an investigational agent within the last days Patient is currently receiving or has received another investigational agent within weeks prior to day of study Patients receiving any other investigational agent (s) Receiving any other investigational agent Patients who are currently receiving any other investigational agent Patients must not be receiving any other investigational agent Receiving other investigational agent At least days have passed since receiving any investigational agent at the time of registration Currently receiving an investigational agent Receiving or less than days since receiving any other concurrent cytotoxic, biologic agent(s) or investigational agent PHASE I: Patients who are receiving any other investigational agent PHASE II: Patients who are receiving any other investigational agent Receiving any other investigational agent(s) or has received an investigational agent within the last days Receiving any other investigational agent(s) or has received an investigational agent within the last days Receiving any other investigational agent(s) or has received an investigational agent within the last days Patients who are receiving any other investigational agent Receiving any other investigational agent which would be considered as a treatment for the lymphoma Receiving any other investigational agent Patient is receiving any other investigational agent Patients must not be receiving any other investigational agent Receiving any other investigational agent Patients who were currently receiving any other investigational agent. Patients receiving other investigational agent Currently receiving another investigational agent Receiving any other concurrent cytotoxic, biologic agent(s) or investigational agent Receiving another investigational agent ( day wash-out required prior to first dose) Patients that are receiving any other investigational agent Receiving any investigational agent currently, or within weeks of day of treatment on this study Participants may not be receiving any other study agent Patients receiving an investigational agent within days before enrollment Currently receiving a study therapy or if they had an investigational agent within weeks at the time of enrollment. Patients must not be receiving any other investigational agent Patients may not be receiving any other investigational agent with therapeutic anticancer intent Receiving any other investigational agents or receipt of another investigational agent within weeks of study entry Patients may not be receiving nor have received any other investigational agent =< weeks prior to study registration Patients who are receiving any other investigational agent Receiving other investigational agent Patients receiving other investigational agent Patients receiving any other current investigational therapeutic agent. Receiving any other investigational agent Patients may not be receiving any other investigational agent with therapeutic anticancer intent The participant is receiving any other investigational agent(s) Patients receiving any other investigational agent(s) Patients may not be receiving any other investigational agent Receiving any other investigational agent Receiving any approved or investigational anti-cancer agent other than those provided for in this study Receiving any agent classified as an antioxidant Patient who is receiving investigational agent(s) as part of another clinical study at the time of screening or who anticipates receiving investigational agent(s) during their scheduled radiotherapy and concomitant daily temozolomide therapy (e.g. through the BMX, MRZ , and BMX - studies) Patient must not be receiving any other anti-cancer agent The participant is receiving any other investigational agent(s). The participant is receiving any other investigational agent(s).